Company Hangzhou Tigermed Consulting Co., Ltd OTC Markets

Equities

HNGZY

US41044T1088

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Hangzhou Tigermed Consulting Co., Ltd

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 16:43:36 19/12/2023 GMT			5-day change	1st Jan Change
4.2 ^USD	-4.55%		-.--%	-.--%

06-18	Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes	CI
06-14	Tigermed Consulting Assures Normal Operations Amid Share Price Fluctuations	MT

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows:

- provision of clinical trial services and related technological services (51.8%);

- provision of clinical research consulting services (48.2%).

China accounts for 46% of sales.

CNY in Million	2022	Weight	2023	Weight	Delta
Clinical Trial Technical Services 56.4 %	4,125	58.2 %	4,168	56.4 %	+1.04%
Clinical Trial-related Services and Laboratory Services 42.3 %	2,876	40.6 %	3,121	42.3 %	+8.51%
Other Business 1.3 %	84	1.2 %	95	1.3 %	+13.10%

CNY in Million	2022	Weight	2023	Weight	Delta
China 57.3 %	3,602	50.8 %	4,235	57.3 %	+17.57%
Overseas 42.7 %	3,484	49.2 %	3,150	42.7 %	-9.60%

Managers	Title	Age	Since
Xiao Chun Cao CEO	Chief Executive Officer	55	31/12/04
Hao Wu PSD	President	56	31/12/19
Xiao Ping Ye CHM	Chairman	61	-
Cheng Cheng Yang DFI	Director of Finance/CFO	50	31/08/22
Zeng Yu Wen COO	Chief Operating Officer	43	28/02/10
Xiaori Li SEC	Corporate Secretary	41	16/09/21
Helen Yin PRN	Corporate Officer/Principal	-	-
Abe Li PRN	Corporate Officer/Principal	-	-
Li Li Meng PRN	Corporate Officer/Principal	49	31/07/09
Qiang Wu PRN	Corporate Officer/Principal	51	31/12/06

Members of the board	Title	Age	Since
Xiao Chun Cao CEO	Chief Executive Officer	55	31/12/04
Bing Hui Zhang CHM	Chairman	61	27/04/20
Xiao Ping Ye CHM	Chairman	61	-
Zhi Min Chen BRD	Director/Board Member	64	-
Hua Gang Yuan BRD	Director/Board Member	51	24/04/23
Kai Yu Liu BRD	Director/Board Member	54	31/03/20
Hao Wu PSD	President	56	31/12/19
Zeng Yu Wen COO	Chief Operating Officer	43	28/02/10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	123,124,800	123,124,800 ( 100.00 %)	0	69.68 %
Stock B	1	741,823,770	479,600,004 ( 64.65 %)	0

Name	Equities	%	Valuation
Sands Capital Management LLC 10.82 %	13,319,131	10.82 %	56 M $
E Fund Management Co., Ltd. 9.812 %	12,081,409	9.812 %	51 M $
Baillie Gifford & Co. 8.301 %	10,220,000	8.301 %	43 M $
Ninety One UK Ltd. 6.141 %	7,560,500	6.141 %	32 M $
Canada Pension Plan Investment Board 6.007 %	7,395,500	6.007 %	31 M $
UBS Asset Management Switzerland AG 5.104 %	6,283,832	5.104 %	26 M $
Bank of Communications Schroder Fund Management Co., Ltd. 4.485 %	5,521,937	4.485 %	23 M $
BlackRock Fund Advisors 1.775 %	2,185,400	1.775 %	9 M $
Huatai-PineBridge Fund Management Co., Ltd. 1.520 %	1,871,900	1.520 %	8 M $
Principal Global Investors (Hong Kong) Ltd. 1.391 %	1,712,900	1.391 %	7 M $

Name	Equities	%	Valuation
Xiao Ping Ye 74.09 %	132,929,656	74.09 %	990 M $
Xiao Chun Cao 21.60 %	38,746,330	21.60 %	288 M $
Yin Zhuan 5.696 %	10,220,000	5.696 %	76 M $
Xiaori Li 0.006164 %	11,058	0.006164 %	82 324 $

Name	Equities	%	Valuation
Xiao Ping Ye 7.775 %	44,309,885	7.775 %	330 M $
Zhong Ou Asset Management Co., Ltd 6.480 %	36,926,806	6.480 %	275 M $
Bank of Communications Schroder Fund Management Co., Ltd. 3.989 %	22,733,132	3.989 %	169 M $
Temasek Holdings Pte Ltd. (Investment Management) 3.419 %	19,483,875	3.419 %	145 M $
Hwabao WP Fund Management Co., Ltd. 2.787 %	15,882,273	2.787 %	118 M $
Xiao Chun Cao 2.266 %	12,915,444	2.266 %	96 M $
China Merchants Fund Management Co., Ltd. 1.902 %	10,838,196	1.902 %	81 M $
Xiao Li Shi 1.881 %	10,721,575	1.881 %	80 M $
HuaAn Fund Management Co., Ltd. 1.500 %	8,547,686	1.500 %	64 M $
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) 1.143 %	6,512,989	1.143 %	48 M $

Name	Equities	%	Valuation
FRONTAGE HOLDINGS CORPORATION 61.84%	1,258,984,090	61.84%	185,070,661 $
DREAMCIS, INC. 59.57%	14,123,680	59.57%	33,255,052 $
HANGZHOU TIGERMED CONSULTING CO., LTD 0.69%	3,909,800	0.69%	29,107,601 $
ANHUI WANBANG PHARMACEUTICAL TECHNOLOGY CO., LTD. 1.53%	776,850	1.53%	4,847,272 $

Hangzhou Tigermed Consulting Co., Ltd.

20/F Block 8, Room 2001-2010 No.19 Jugong Road, Xixiang Street

310051, Hangzhou

+86 571 2888 7227

http://www.tigermed.net

address Hangzhou Tigermed Consulting Co., Ltd(HNGZY)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

50.36 CNY

Average target price

74.23 CNY

Spread / Average Target

+47.40%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+35.14%	51.51B
IQVIA HOLDINGS INC.	-7.43%	39.03B
LONZA GROUP AG	+34.61%	38.91B
CELLTRION, INC.	-10.62%	26.68B
ICON PUBLIC LIMITED COMPANY	+11.63%	26.13B
ALNYLAM PHARMACEUTICALS, INC.	-17.77%	19.91B
UNITED THERAPEUTICS CORPORATION	+40.52%	13.71B
MEDPACE HOLDINGS, INC.	+30.70%	12.38B
BIO-TECHNE CORPORATION	-3.41%	11.74B

Other Biotechnology & Medical Research